Furthermore, expression data from the Tumor Immune Dysfunction and Exclusion (TIDE) database, which includes expression data from bladder cancer patients treated with the ICI therapeutic anti-PD-L1, revealed that TMB was associated with the best response among nearly all other cancers. This evidence concerns the gene CD274 and urinary bladder carcinoma.